{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+T-Cell+Lymphoma+%28CTCL%29&page=2", "query": { "condition": "Cutaneous T-Cell Lymphoma (CTCL)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+T-Cell+Lymphoma+%28CTCL%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T16:21:44.571Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00611208", "title": "A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Lymphomas", "T-cell Leukemia", "Sezary Syndrome", "Mycosis Fungoides", "Cutaneous T-cell Lymphoma (CTCL)" ], "interventions": [ { "name": "A-dmDT390-bisFv(UCHT1)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Virogen Biotechnology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2008-01", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Dallas, Texas + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00611208" }, { "nct_id": "NCT00341939", "title": "Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer", "Breast Cancer", "Cutaneous T-Cell Lymphoma", "Lung Cancer", "Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 484, "start_date": "2004-09-07", "completion_date": "2024-06-12", "has_results": false, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00341939" }, { "nct_id": "NCT03235869", "title": "Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cutaneous T Cell Lymphoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-03-01", "completion_date": "2023-03-01", "has_results": false, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03235869" }, { "nct_id": "NCT00724061", "title": "Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Pegylated interferon α-2b", "type": "BIOLOGICAL" }, { "name": "Psoralens with ultraviolet light A", "type": "OTHER" }, { "name": "Narrowband-ultraviolet light B", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 7, "start_date": "2008-09", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-12-12", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00724061" }, { "nct_id": "NCT00961220", "title": "O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7" ], "interventions": [ { "name": "Carmustine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "O6-Benzylguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 17, "start_date": "2010-02-01", "completion_date": "2014-04-08", "has_results": true, "last_update_posted_date": "2018-05-22", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cleveland, Ohio • Columbus, Ohio", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00961220" }, { "nct_id": "NCT01199562", "title": "Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematopoietic/Lymphoid Cancer", "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Aplastic Anemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Cytomegalovirus Infection", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Isolated Plasmacytoma of Bone", "Mast Cell Leukemia", "Meningeal Chronic Myelogenous Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Primary Systemic Amyloidosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Secondary Myelofibrosis", "Splenic Marginal Zone Lymphoma", "Stage 0 Chronic Lymphocytic Leukemia", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Adult T-cell Leukemia/Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage I Small Lymphocytic Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage II Adult T-cell Leukemia/Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Multiple Myeloma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "infection prophylaxis and management", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "DNA analysis", "type": "GENETIC" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "ganciclovir", "type": "DRUG" }, { "name": "valganciclovir", "type": "DRUG" }, { "name": "foscarnet sodium", "type": "DRUG" }, { "name": "antiviral therapy", "type": "PROCEDURE" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" } ], "intervention_types": [ "PROCEDURE", "OTHER", "GENETIC", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2010-12", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01199562" }, { "nct_id": "NCT01396070", "title": "Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma (NHL)", "Cutaneous Lymphoma", "Cutaneous T-cell Lymphoma (CTCL)", "Mycosis Fungoides", "Sezary Syndrome" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Youn Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2011-05", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01396070" }, { "nct_id": "NCT00290628", "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Diamond-blackfan Anemia", "Fanconi Anemia", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "radiation therapy", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 43, "start_date": "1999-10", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290628" }, { "nct_id": "NCT00004189", "title": "Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "becatecarin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 3, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004189" }, { "nct_id": "NCT01871727", "title": "A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Persistent or Recurrent Cutaneous T-Cell Lymphoma" ], "interventions": [ { "name": "E7777 9 mcg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2013-05-30", "completion_date": "2021-12-14", "has_results": true, "last_update_posted_date": "2024-11-13", "last_synced_at": "2026-06-10T16:21:44.571Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871727" } ] }